Clostridium difficile Infections Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018
Clostridium difficile is a bacterium which infects the bowel and caused diarrhea. This infection is most commonly seen in people who were recently been treated with antibiotics and it can be spread easily to others. Clostridium difficile is also called as C. difficile or C.diff. C.diff infections may cause serious bowel problems. Symptoms of C.diff infections includes watery diarrhea, painful cramps in tummy, dehydration, dry mouth, head ache, loss of weight and appetite etc.
C.diff can be diagnosed by enzyme immunoassay, polymerase chain reaction, GDH or EIA. Treatment for Clostridium difficile infection includes antibiotics course.
By Trial Phase, Clostridium difficile Infections pipeline drugs are segmented as:
- Preclinical Trials
- Phase 1
- Phase 2
- Phase 3
- Phase 4
By Company, Clostridium difficile Infections pipeline drugs are segmented as:
- Synthetic Biologics
- Da Volterra
- Pfizer Inc.
- Valneva SE
- Seres Therapeutics
- Summit Therapeutics
- Rebiotix Inc.
By Drugs, Clostridium difficile Infections pipeline drugs are segmented as:
By Type of Condition Clostridium difficile Infections pipeline drugs are segmented as:
- Systemic JIA
- Polyarticular arthritis,rheumatoid factor negative/ rheumatoid factor positive
- Psoriatic arthritis
- Enthesitis-related arthritis
- Undifferentiated arthritis
By Route of Administration, Clostridium difficile Infections pipeline drugs are segmented as:
- In July 2016, Valneva SE completed Phase II study for its prophylactic vaccine candidate VLA84 targeting primary prevention of difficile infection (CDI). The study met its primary endpoint in terms of identifying the dose/formulation with the highest seroconversion rate against both toxins A and B and confirmed the favorable safety profile observed in Phase
- In June 2017, Seres Therapeutics, Inc. initiated Phase 3 clinical study of its SER-109 (ECOSPOR III) in patients with multiply recurrent difficile infection and also commenced Phase 1b clinical trial evaluating SER-262 in patients with primary Clostridium difficile infection (CDI).
- On May 11, 2017 The U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation for SYN-004 (ribaxamase) of Synthetic Biologicsfor the prevention of Clostridium difficile infection.
- In October 2015, RBX2660 of Rebiotix was grated orphan drug status and fast track designation from U.S.FDA for its potential to prevent recurrent C. diff. infection.
Clostridium difficile InfectionsDisease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Clostridium difficile Infections treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Clostridium difficile Infections disease pipeline drugs development. This report studies the dynamics of the Clostridium difficile Infections Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Clostridium difficile Infections disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Key Features of the Report:
- Provides the information related to universities and research institutes working in the therapeutics development
- Report comprehensively covers the all active and discontinued studies
- Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
- Presents the prominent targets for drug development in each stage of clinical trial
- Provides the in-depth analysis on the each drug candidates in the clinical trial phases